Novan Inc (NOVN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Novan Inc (NOVN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile


  • Products Id :- GDPH355644D
  • |
  • Pages: 47
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Novan Inc (Novan) is a clinical-stage pharmaceutical company that develops nitric oxide therapies for the treatment of dermatological and oncovirus-mediated diseases. The company's pipeline products are being developed for the treatment of acne vulgaris; genital warts; for onychomycosis and for treatment of psoriasis and atopic dermatitis. Novan uses its proprietary technology Nitricil, to customize macromolecular delivery of nitric oxide and store gaseous species which result in nitric oxide-releasing new chemical entities for healthcare applications. The company's products find application in the treatment of dermatology disorders. It works in collaboration with academic institutions, public and private companies and other universities. Novan is headquartered in Morrisville, North Carolina, the US.

Novan Inc (NOVN)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Novan Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Novan Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Novan Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Novan Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Novan Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Novan Inc, Pharmaceuticals & Healthcare, Deal Details 11

Asset Purchase 11

Novan Acquires Intellectual Property Rights From KNOW Bio 11

Venture Financing 12

Novan Raises Additional USD2.4 Million in Venture Financing 12

Novan Raises USD30.4 Million in Financing Round 13

Novan Raises Additional USD39.7 Million in Venture Financing 14

Novan Raises USD10.3 Million in Venture Financing 15

Novan Raises USD3.5 Million in Venture Financing 16

Novan Raises USD 11 Million In Series D Financing 17

Licensing Agreements 18

Sato Pharma Amends Licensing Agreement with Novan 18

Know Bio Enters into Sub-Licensing Agreement with Novan 20

Know Bio Enters into Licensing Agreement with Novan 21

Novan Enters into Licensing Agreement with University of Akron Research Foundation 22

Equity Offering 23

Novan Raises USD38 Million in Public Offering of Shares 23

Novan Plans to Raise Funds through Public Offering of Shares 24

Novan Raises USD51.9 Million in IPO 25

Novan Inc-Key Competitors 26

Novan Inc-Key Employees 27

Novan Inc-Locations And Subsidiaries 28

Head Office 28

Recent Developments 29

Financial Announcements 29

May 12, 2017: Novan Reports First Quarter 2017 Financial Results 29

Mar 20, 2017: Novan Reports Fourth Quarter and Full Year 2016 Financial Results 30

Corporate Communications 32

Apr 12, 2018: Novan Advances Organization and Strengthens Leadership Team 32

Feb 21, 2018: Dr. Eugene Sun Appointed to Novan Board of Directors 33

Jan 19, 2018: Novan Announces Resignation Of William L. Hodges As Interim Chief Financial Office 34

Sep 26, 2017: Machelle Sanders Appointed to Novan Board of Directors 35

Aug 16, 2017: Novan Appoints Paula Brown Stafford, Chief Development Officer, to Board of Directors 36

Jun 05, 2017: Novan Announces Leadership Adjustments and Business Update 37

Mar 22, 2017: Novan Reshapes Executive Management Team 39

Clinical Trials 41

May 17, 2018: SB208 Increases Daily Nail Growth Rate over Four Weeks of Treatment 41

Jan 11, 2018: Novan to Present Positive Phase 2 Results for SB208 Antifungal Program at Winter Clinical Dermatology Conference 42

Dec 05, 2017: Novan Announces First Patient Dosed in Phase 1b Atopic Dermatitis Trial with SB414 44

Apr 27, 2017: Novan Presents Preclinical Data from Inflammatory Skin Diseases Program 45

Apr 12, 2017: Novan Reports Positive Topline Results with SB208 in Phase 2 Trial 46

Appendix 47

Methodology 47

About GlobalData 47

Contact Us 47

Disclaimer 47

List of Figures

Novan Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Novan Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Novan Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Novan Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Novan Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Novan Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Novan Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Novan Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

List of Tables

Novan Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Novan Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Novan Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Novan Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Novan Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Novan Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Novan Acquires Intellectual Property Rights From KNOW Bio 11

Novan Raises Additional USD2.4 Million in Venture Financing 12

Novan Raises USD30.4 Million in Financing Round 13

Novan Raises Additional USD39.7 Million in Venture Financing 14

Novan Raises USD10.3 Million in Venture Financing 15

Novan Raises USD3.5 Million in Venture Financing 16

Novan Raises USD 11 Million In Series D Financing 17

Sato Pharma Amends Licensing Agreement with Novan 18

Know Bio Enters into Sub-Licensing Agreement with Novan 20

Know Bio Enters into Licensing Agreement with Novan 21

Novan Enters into Licensing Agreement with University of Akron Research Foundation 22

Novan Raises USD38 Million in Public Offering of Shares 23

Novan Plans to Raise Funds through Public Offering of Shares 24

Novan Raises USD51.9 Million in IPO 25

Novan Inc, Key Competitors 26

Novan Inc, Key Employees 27

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Novan Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license
Single User License
USD 250 INR 17500
Site License
USD 500 INR 35000
Corporate User License
USD 750 INR 52500

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com